Anything seems possible, e.g., hematological indications + potential niche market opportunities (not oncology) are licensed to, for example, Orion, and solid ones to, for example, Bayer. HR MDS trial activities are likely related to running the ongoing phase 2 (the active phase of the study will likely continue for several more months) as well as f2b/f3 preparations.
3 Likes